Champions Oncology (NASDAQ:CSBR) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of Champions Oncology (NASDAQ:CSBR) from a buy rating to a hold rating in a research report released on Thursday morning, Zacks.com reports.

According to Zacks, “Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland. “

CSBR has been the subject of several other reports. Benchmark began coverage on Champions Oncology in a research note on Wednesday, November 27th. They set a buy rating and a $11.00 price objective for the company. ValuEngine raised Champions Oncology from a hold rating to a buy rating in a report on Tuesday, January 7th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $11.63.

Shares of NASDAQ CSBR traded down $0.27 during trading on Thursday, hitting $8.24. The company had a trading volume of 53,358 shares, compared to its average volume of 38,804. The firm has a market capitalization of $95.40 million, a price-to-earnings ratio of -91.56 and a beta of 1.27. The stock has a fifty day simple moving average of $7.82 and a two-hundred day simple moving average of $6.52. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 1.62. Champions Oncology has a fifty-two week low of $4.98 and a fifty-two week high of $12.80.

Champions Oncology (NASDAQ:CSBR) last released its quarterly earnings results on Monday, December 16th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.04. The firm had revenue of $7.63 million during the quarter, compared to the consensus estimate of $7.83 million. Champions Oncology had a negative net margin of 3.35% and a negative return on equity of 45.46%. On average, analysts anticipate that Champions Oncology will post 0.03 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in CSBR. Marshall Wace LLP acquired a new stake in Champions Oncology during the 1st quarter worth $99,000. Susquehanna International Group LLP raised its holdings in Champions Oncology by 51.0% in the 2nd quarter. Susquehanna International Group LLP now owns 24,510 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 8,279 shares during the last quarter. Tocqueville Asset Management L.P. raised its holdings in Champions Oncology by 69.1% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 134,568 shares of the biotechnology company’s stock valued at $760,000 after acquiring an additional 55,000 shares during the last quarter. BlackRock Inc. lifted its stake in Champions Oncology by 12.0% in the 2nd quarter. BlackRock Inc. now owns 137,027 shares of the biotechnology company’s stock worth $1,073,000 after purchasing an additional 14,733 shares in the last quarter. Finally, River & Mercantile Asset Management LLP purchased a new position in Champions Oncology in the 2nd quarter worth approximately $1,082,000. Institutional investors own 49.62% of the company’s stock.

Champions Oncology Company Profile

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Featured Story: What is a stock split?

Get a free copy of the Zacks research report on Champions Oncology (CSBR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.